Is Nintedanib effective in treating interstitial pneumonia?

In two studies of patients with idiopathic pulmonary fibrosis, those taking nintedanib had a smaller decrease in FVC than those taking a placebo, meaning nintedanib slowed the progression of the disease. The average patient's FVC before treatment was between 2600 and 2700 milliliters (ml). In the first study, patients taking nintedanib experienced an average decrease in FVC of 115ml over 1 year. In the second study, the average drop in nintedanib was 114ml. Further analysis of the results from the two main studies, which took into account that some patients discontinued treatment, confirmed the superiority of nintedanib over placebo, although the difference in FVC between the two was less clear.